The FDA released new information on an initiative using artificial intelligence to speed up the drug approval process. HealthDay News — The U.S. Food and Drug Administration (FDA) is moving to speed ...

The FDA has approved Auvelity (dextromethorphan HBr/bupropion HCl) for Alzheimer disease agitation, providing a non-antipsychotic option based on ADVANCE-1 and ACCORD-2 data.

Higher vitamin D levels in early midlife are associated with lower tau deposition in later midlife among adults without dementia.

There is a greater risk for the development of behavioral problems among children born with congenital heart disease.

What were the most significant improvements seen in the Myasthenia Gravis-Activities of Daily Living and Quantitative ...

Recent data show high interest and use of spiritual practices and manual therapies among older individuals, particularly those with depression.

Adenotonsillectomy appears to be an effective way to resolve obstructive sleep apnea and improve sleep efficacy for many children.

Eptinezumab plus education reduces monthly migraine days in adults with chronic migraine and medication-overuse headache.

Cognitive function may deteriorate preceding cardiovascular events among older adults, highlighting the value of early cognitive screening.

The FDA has granted accelerated approval to Otarmeni™ (lunsotogene parvec-cwha), the first gene therapy for pediatric and adult patients with OTOF-related sensorineural hearing loss.

FDA issues a Complete Response Letter to Grace Therapeutics for GTx-104, an intravenous nimodipine formulation for aneurysmal subarachnoid hemorrhage.